Migraine Spray Clinical Trials include two phases. 502 patients have been treated by the drug in these phases. Phase I is mainly focused on the preliminary test of the efficacy, effect profile, and safety of the drug. Also, in this phase, safe and effective doses of the drug have been determined.

In Phase II, a thorough result of the patients’ treatment by Migraine Spray is presented. A qualitative analysis of the results is also provided to show the treatment efficacy of the drug. The quantitative analysis provides a statistical view of the treatment results. About 90 percent reduction of migraine headache by Migraine Spray and 93 percent of patients’ satisfaction of the treatments are remarkable achievements of the clinical trials in Phase II.